This information is confidential and usually cannot be seen by the public.What Feder advocated was thatThe NIH could require grantees to make public disclosures of their paid arrangements with pharmaceutical, investment and other companies, as well as their ownership of stock and stock options, as a condition of having their medical research funded by the government.So this letter from 2005 presag